Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
- PMID: 24875380
- DOI: 10.2174/1389450115666140528151649
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Abstract
Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease at cellular and molecular level however have helped researchers in devising novel strategies for therapy. These directed therapies limit cancer growth by targeting specific molecules related with tumor progression. Such strategies have shown to be more effective than chemotherapy and radiotherapy and can be complemented to existing therapeutic paradigm in augmenting beneficial outcome. Lung cancer could benefit from such innovative therapy. RNA interference (RNAi) is a sequence-specific gene silencing mechanism and, since its discovery widespread applications have pointed it as a powerful tool in cancer treatment. Several on-going clinical trials have been successfully demonstrating its potential as a novel therapeutic, including in the treatment of NSCLC. Here, we revise the recent findings concerning the therapeutic effects of molecular variations associated with NSCLC and where targeted therapies stand in its treatment, with special focus on RNAi-mediated gene silencing as a powerful strategy for NSCLC treatment.
Similar articles
-
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613. J Cancer Res Ther. 2016. PMID: 28230005 Review.
-
Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Oncotarget. 2015 Feb 20;6(5):3335-45. doi: 10.18632/oncotarget.2793. Oncotarget. 2015. PMID: 25595901 Free PMC article.
-
From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Expert Rev Anticancer Ther. 2017 Feb;17(2):157-165. doi: 10.1080/14737140.2017.1273111. Epub 2017 Jan 5. Expert Rev Anticancer Ther. 2017. PMID: 27984919 Review.
-
Lung Cancer: Management.FP Essent. 2018 Jan;464:27-30. FP Essent. 2018. PMID: 29313655 Review.
-
[New therapeutic strategies and current research in inoperable locally advanced non small-cell lung cancers (stage IIIB)].Bull Cancer. 1997 Apr;84(4):413-9. Bull Cancer. 1997. PMID: 9238166 Review. French.
Cited by
-
Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy.ACS Omega. 2023 May 24;8(22):20056-20065. doi: 10.1021/acsomega.3c02331. eCollection 2023 Jun 6. ACS Omega. 2023. PMID: 37305321 Free PMC article.
-
MicroRNA-374b-5p Functions as a Tumor Suppressor in Non-Small Cell Lung Cancer by Targeting FOXP1 and Predicts Prognosis of Cancer Patients.Onco Targets Ther. 2020 May 15;13:4229-4237. doi: 10.2147/OTT.S243221. eCollection 2020. Onco Targets Ther. 2020. PMID: 32523358 Free PMC article.
-
The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.Life (Basel). 2022 Oct 19;12(10):1640. doi: 10.3390/life12101640. Life (Basel). 2022. PMID: 36295075 Free PMC article. Review.
-
Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma.Sci Rep. 2017 Aug 17;7(1):8649. doi: 10.1038/s41598-017-08851-9. Sci Rep. 2017. PMID: 28819306 Free PMC article.
-
PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.Bioorg Med Chem Lett. 2016 Oct 15;26(20):4884-4887. doi: 10.1016/j.bmcl.2016.09.030. Epub 2016 Sep 13. Bioorg Med Chem Lett. 2016. PMID: 27650927 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical